Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Milia-Like Papules and Ulcerated Nodules in a Man With Bartter Syndrome.

Actas dermo-sifiliograficas·2025
Same author

Generalized Pustular Psoriasis: Review and Consensus of the Psoriasis Group of the Spanish Academy of Dermatology and Venereology.

Actas dermo-sifiliograficas·2025
Same author

Psychotropic Drugs: A Practical Guide for Use in Dermatology.

Actas dermo-sifiliograficas·2025
Same author

[Translated article] Methotrexate-Induced Gouty Arthritis in Psoriatic Patient.

Actas dermo-sifiliograficas·2025
Same author

Methotrexate-Induced Gouty Arthritis in Psoriatic Patient.

Actas dermo-sifiliograficas·2025
Same author

[Translated article] Updated Perspective from the Spanish Psoriasis Working Group (GPS) on Biosimilar Drug Use in Moderate-to-Severe Psoriasis.

Actas dermo-sifiliograficas·2025

Related Experiment Video

Updated: May 13, 2026

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
06:07

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors

Published on: August 5, 2022

Methotrexate: new therapeutic approaches.

L Puig1

  • 1Servicio de Dermatología, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, España.

Actas Dermo-Sifiliograficas
|February 26, 2013
PubMed
Summary

Methotrexate is now considered a first-line systemic treatment for psoriasis, supported by recent pharmacokinetic data and improved subcutaneous formulations. Its cost-effectiveness surpasses that of several biologic agents, making it a valuable therapeutic option.

Keywords:
Clinical trialsCost-effectivenessCoste-eficaciaEnsayos clínicosFarmacocinéticaMecanismo de acciónMechanism of actionMethotrexateMetotrexatoPharmacokineticsPsoriasis

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics
12:28

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics

Published on: January 11, 2019

Related Experiment Videos

Last Updated: May 13, 2026

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
06:07

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors

Published on: August 5, 2022

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics
12:28

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics

Published on: January 11, 2019

Area of Science:

  • Dermatology
  • Pharmacology
  • Health Economics

Background:

  • Methotrexate (MTX) has a long history in psoriasis treatment since 1958, but robust scientific evidence has been limited until recently.
  • Recent advancements include detailed pharmacokinetic and mechanism of action data for MTX.
  • New subcutaneous formulations have enhanced MTX bioavailability, efficacy, and ease of administration.

Purpose of the Study:

  • To evaluate the current standing of methotrexate as a first-line therapy for psoriasis.
  • To assess the comparative efficacy and cost-effectiveness of methotrexate against biologic agents and other systemic treatments.

Main Methods:

  • Review of recent clinical trials comparing methotrexate with biologic agents.
  • Analysis of pharmacokinetic and mechanism of action data for methotrexate.
  • Evaluation of incremental cost-effectiveness ratios (ICERs).

Main Results:

  • Recent clinical trials position methotrexate as a first-line therapy among classic systemic treatments for psoriasis.
  • Subcutaneous methotrexate demonstrates improved bioavailability and efficacy.
  • The incremental cost-effectiveness ratio of subcutaneous methotrexate is superior to ciclosporin, adalimumab, and infliximab.

Conclusions:

  • Methotrexate, particularly in subcutaneous formulations, is a highly effective and cost-effective first-line systemic treatment for psoriasis.
  • Updated scientific evidence supports its established role in psoriasis management.
  • Methotrexate offers a superior cost-effectiveness profile compared to several biologic therapies.